Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, IPOs, acquisition...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will p...
Image source: The Motley Fool. Calithera Biosciences, Inc (NASDAQ: CALA) Q3 2021 Earnings Call Nov 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences, Inc (CALA) Q3 2021 Earnings Call Transcrip...
Calithera Biosciences, Inc. (CALA) Q3 2021 Earnings Conference Call November 09, 2021 05:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, President & Chief Executive Officer Emil Kuriakose - Chief Medical Officer Conference Call Participant...
-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of September 30, 2021 -- -- Conferen...
Calithera Biosciences (NASDAQ:CALA) announces its decision to terminate the company's phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. Shares drop more than 33% premarket. The phase 2 study was designe...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the promotion of current vice president and head of clinical development, Dr. Emil T. Kuriakose, to chie...
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as well as the ongoing trial of CB-280 for the treatment of cyst...
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s third quarter 2021 financial results will be released on Tuesday, Novembe...
Calithera Biosciences (NASDAQ:CALA) has added ~4.7% in the pre-market after the company reported interim Phase 1b data from a dose-escalation trial designed to evaluate CB-280 in adults with cystic fibrosis (CF). Data were generated from the first 24 subjects (18 treated with C...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...